An analysis of more 13,000 children with type 1 diabetes suggests puberty onset in children with type 1 diabetes is occurring earlier now than it had been at the turn of the century.
In the PROTECT trial, teplizumab preserved β-cell function in newly diagnosed type 1 diabetes patients, slowing the decline of C-peptide levels, but key secondary endpoints, such as time in range and HbA1c, showed numerical trends without statistical significance.
Despite access to care and health insurance, Hispanic and non-Hispanic Black individuals with diabetes experience poorer glycemic control compared to non-Hispanic White counterparts, revealing persistent racial disparities in healthcare.
Results show engaging in unstructured physical activities, even those of low intensity and carried out in the morning and early afternoon, is linked to reduced average glucose levels throughout the day and night.
In the overall population of more than 1.3 million US adults, 37% of patients reported being diagnosed with T1D after 30 years, with men and racial or ethnic minorities diagnosed later compared with women and non-Hispanic White adults.